Related coverage linked through entity extraction aliases.
Feb 14, 2026
Life sciences companies are integrating AI into clinical trial operations to reduce administrative burden and improve efficiency, while the biotechnology sector experiences a structural transformation driven by AI industrialization and institutional capital.
Feb 13, 2026
Moderna reported Q4 2025 revenue of $700 million and full-year revenue of $1.9 billion, beating estimates while cutting operating expenses by $2.2 billion. The FDA refused to file the company's seasonal flu vaccine application.
Feb 12, 2026
International researchers have identified a specific antibody mutation that causes rare but serious blood clots after adenovirus-based COVID-19 vaccines or natural adenovirus infection, providing a roadmap for safer vaccine design.
Feb 12, 2026
The mRNA therapy market is forecast to grow from USD 13.6 billion in 2025 to USD 70.0 billion by 2035 at a 17.8% CAGR, driven by expanding applications beyond vaccines into oncology, rare diseases, and infectious disease treatments including genital herpes.
Feb 13, 2026
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
Feb 13, 2026
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Feb 13, 2026
The FDA will review Moderna's mRNA-1010 seasonal influenza vaccine after the company proposed a revised regulatory pathway, setting an August 2026 decision date following an earlier refusal-to-file letter.
Dec 09, 2025
Moderna and Merck announced median five-year follow-up data showing intismeran autogene in combination with Keytruda reduced the risk of melanoma recurrence or death by 49% in high-risk patients following complete resection.
Feb 12, 2026
The European Commission has granted marketing authorization for Moderna's mNEXSPIKE (mRNA-1283) COVID-19 vaccine for individuals aged 12 years and older across all 27 EU member states plus Iceland, Liechtenstein and Norway.
Feb 10, 2026
The FDA reversed its refusal to review Moderna's mRNA flu vaccine application after the company amended its submission. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and older, with a decision expected by August 5, 2026.
Feb 13, 2026
The FDA mandated febrile seizure warnings for flu vaccines and rejected Moderna's mRNA flu vaccine application, with a political appointee overruling agency staff despite no safety concerns identified.
